← Back to Search

Device

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Phase 3
Waitlist Available
Led By Ignace Vergote, MD
Research Sponsored by NovoCure Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial tests a new device called TTFields, which uses electric fields to treat ovarian cancer, along with a chemotherapy drug. It targets patients whose cancer does not respond to usual treatments. The device works by disrupting cancer cell division, causing the cells to die or stop growing. TTFields have been shown to reduce cancer cell counts and enhance the effectiveness of chemotherapy in various earlier research.

Eligible Conditions
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Next progression-free survival
Time to first and second subsequent treatment
Time to undisputable deterioration in health-related quality of life (HRQoL)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NovoTTF-100L(O)Experimental Treatment2 Interventions
Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
Group II: Best Standard of CareActive Control1 Intervention
Patients receive best standard of care with weekly Paclitaxel
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NovoTTF-100L(O)
2019
Completed Phase 3
~540
Paclitaxel
2011
Completed Phase 4
~5450

Find a Location

Who is running the clinical trial?

NovoCure Ltd.Lead Sponsor
62 Previous Clinical Trials
5,451 Total Patients Enrolled
Ignace Vergote, MDPrincipal InvestigatorUniversity Hospitals Leuven, Leuven Cancer Institute
1 Previous Clinical Trials
116 Total Patients Enrolled
~81 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top